Dynamic Reorganization of Microtubule and Glioma Invasion.
cytoskeletons
glioma
invasion
microtubules
Journal
Acta medica Okayama
ISSN: 0386-300X
Titre abrégé: Acta Med Okayama
Pays: Japan
ID NLM: 0417611
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
24
8
2019
pubmed:
24
8
2019
medline:
7
2
2020
Statut:
ppublish
Résumé
Gliomas are characterized as highly diffuse infiltrating tumors, and currently available treatments such as surgery, radiation and chemotherapy are unfeasible or show limited efficacy against these tumors. Recent genetic and epigenetic analyses of glioma have revealed increasing evidence of the role of driver genetic alterations in glioma development and led to the identification of prognostic factors. Despite these findings, the survival rates of glioma patients remain low, and alternative treatments and novel targets are needed. Recent studies identified neural stem cells as the possible origin of gliomas, and some evidence has revealed shared functions and mechanisms between glioma cells and neurons, also supporting their similarity. The cytoskeleton plays important roles in the migration of normal cells as well as cancer cells. Recent reports have described a role for microtubules, a component of the cytoskeleton, in glioma invasion. Notably, several factors that regulate microtubule functions, such as microtubule-associated proteins, plus-end tracking proteins, or motor proteins, are upregulated in glioma tissues compared with normal tissue, and upregulation of these factors is associated with high invasiveness of glioma cells. In this review, we describe the mechanism of microtubules in glioma invasion and discuss the possibility of microtubule-targeted therapy to inhibit glioma invasion.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
285-297Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (2016) 131: 803-820.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352: 987-996.
Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy- Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME and Ram Z: Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. Jama (2017) 318: 2306-2316.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, OʼRourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R and Sampson JH: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol (2017) 18: 1373-1385.
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M and Weller M: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol (2014) 15: 1100-1108.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L and Cloughesy T: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 370: 709-722.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner- Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Jr. and Mehta MP: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 370: 699-708.
Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A and Ogawa S: Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet (2015) 47: 458-468.
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W and Kros JM: Interim results from the CATNON trial (EORTC study 26053- 22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet (2017) 390: 1645-1653.
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz- Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, OʼNeill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C,Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G and Chin L: The somatic genomic landscape of glioblastoma. Cell (2013) 155: 462-477.
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med (2016) 22: 1314-1320.
Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt- Rosen O, Suva ML, Regev A and Bernstein BE: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 344: 1396-1401.
Suva ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN and Bernstein BE: Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell (2014) 157: 580-594.
Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, Venteicher AS, Hebert CH, Carey CD, Rodig SJ, Shareef SJ, Najm FJ, van Galen P, Wakimoto H, Cahill DP, Rich JN, Aster JC, Suva ML, Patel AP and Bernstein BE: Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell (2017) 20: 233-246. e237.
Ortensi B, Setti M, Osti D and Pelicci G: Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res Ther (2013) 4: 18.
Ichikawa T, Otani Y, Kurozumi K and Date I: Phenotypic Transition as a Survival Strategy of Glioma. Neurol Med Chir (Tokyo) (2016) 56: 387-395.
Sun H, Guo D, Su Y, Yu D, Wang Q, Wang T, Zhou Q, Ran X and Zou Z: Hyperplasia of pericytes is one of the main characteristics of microvascular architecture in malignant glioma. PLoS One (2014) 9: e114246.
Matsukado Y, Maccarty CS and Kernohan JW: The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg (1961) 18: 636-644.
Bell E, Jr. and Karnosh LJ: Cerebral hemispherectomy; report of a case 10 years after operation. J Neurosurg (1949) 6: 285-293.
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ and Chang SM: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 28: 1963-1972.
Burger PC, Heinz ER, Shibata T and Kleihues P: Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg (1988) 68: 698-704.
Earnest Ft, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, Forbes GS and Axley PL: Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology (1988) 166: 823-827.
Plate KH, Breier G, Weich HA and Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 359: 845-848.
Herrlinger U, Schafer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hanel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tuttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W and Glas M: Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol (2016) 34: 1611-1619.
Ishida J, Onishi M, Kurozumi K, Ichikawa T, Fujii K, Shimazu Y, Oka T and Date I: Integrin inhibitor suppresses bevacizumab-induced glioma invasion. Transl Oncol (2014) 7: 292-302. e291.
Otani Y, Ichikawa T, Kurozumi K, Inoue S, Ishida J, Oka T, Shimizu T, Tomita Y, Hattori Y, Uneda A, Matsumoto Y, Michiue H and Date I: Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. Oncogene (2018) 37: 777-786.
Shimizu T, Ishida J, Kurozumi K, Ichikawa T, Otani Y, Oka T, Tomita Y, Hattori Y, Uneda A, Matsumoto Y and Date I: delta-Catenin Promotes Bevacizumab-Induced Glioma Invasion. Mol Cancer Ther (2019) 18: 812-822.
Lucio-Eterovic AK, Piao Y and de Groot JF: Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res (2009) 15: 4589-4599.
de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y and Conrad CA: Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol (2010) 12: 233-242.
Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R and Niclou SP: Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 108: 3749-3754.
Piao Y, Liang J, Holmes L, Henry V, Sulman E and de Groot JF: Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res (2013) 19: 4392-4403.
Otani Y, Ichikawa T, Uneda A, Kurozumi K, Ishida J and Date I: Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma. World Neurosurg (2018) 116: 464-471. e461.
Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M and Bergers G: VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 22: 21-35.
Giese A, Bjerkvig R, Berens ME and Westphal M: Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol (2003) 21: 1624-1636.
Cohen BA, Knopp EA, Rusinek H, Babb JS, Zagzag D and Gonen O: Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy. AJNR Am J Neuroradiol (2005) 26: 2170-2177.
Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS and Canoll P: The role of myosin II in glioma invasion of the brain. Mol Biol Cell (2008) 19: 3357-3368.
Fujimura A, Michiue H, Cheng Y, Uneda A, Tani Y, Nishiki T, Ichikawa T, Wei FY, Tomizawa K and Matsui H: Cyclin G2 promotes hypoxiadriven local invasion of glioblastoma by orchestrating cytoskeletal dynamics. Neoplasia (2013) 15: 1272-1281.
Hayashi K, Michiue H, Yamada H, Takata K, Nakayama H, Wei FY, Fujimura A, Tazawa H, Asai A, Ogo N, Miyachi H, Nishiki T, Tomizawa K, Takei K and Matsui H: Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization. Sci Rep (2016) 6: 23372.
Berges R, Tchoghandjian A, Honore S, Esteve MA, Figarella-Branger D, Bachmann F, Lane HA and Braguer D: The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells. Mol Cancer Ther (2016) 15: 2740-2749.
Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, Nishiyama A, Luo L and Zong H: Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell (2011) 146: 209-221.
Gillespie S and Monje M: An active role for neurons in glioma progression: making sense of Schererʼs structures. Neuro Oncol (2018) 20: 1292-1299.
Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, Fisher JM, Rodman C, Mount C, Filbin MG, Neftel C, Desai N, Nyman J, Izar B, Luo CC, Francis JM, Patel AA, Onozato ML, Riggi N, Livak KJ, Gennert D, Satija R, Nahed BV, Curry WT, Martuza RL, Mylvaganam R, Iafrate AJ, Frosch MP, Golub TR, Rivera MN, Getz G, Rozenblatt-Rosen O, Cahill DP, Monje M, Bernstein BE, Louis DN, Regev A and Suva ML: Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature (2016) 539: 309-313.
Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, Weil S, Horstmann H, Wiestler B, Syed M, Huang L, Ratliff M, Karimian Jazi K, Kurz FT, Schmenger T, Lemke D, Gommel M, Pauli M, Liao Y, Haring P, Pusch S, Herl V, Steinhauser C, Krunic D, Jarahian M, Miletic H, Berghoff AS, Griesbeck O, Kalamakis G, Garaschuk O, Preusser M, Weiss S, Liu H, Heiland S, Platten M, Huber PE, Kuner T, von Deimling A, Wick W and Winkler F: Brain tumour cells interconnect to a functional and resistant network. Nature (2015) 528: 93-98.
Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN and Canoll P: Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia (2006) 53: 799-808.
Katsetos CD, Reginato MJ, Baas PW, DʼAgostino L, Legido A, Tuszyn Ski JA, Draberova E and Draber P: Emerging microtubule targets in glioma therapy. Semin Pediatr Neurol (2015) 22: 49-72.
Scherer HJ: A CRITICAL REVIEW: THE PATHOLOGY OF CEREBRAL GLIOMAS. J Neurol Psychiatry (1940) 3: 147-177.
Zagzag D, Esencay M, Mendez O, Yee H, Smirnova I, Huang Y, Chiriboga L, Lukyanov E, Liu M and Newcomb EW: Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/ CXCR4 expression in glioblastomas: one plausible explanation of Schererʼs structures. Am J Pathol (2008) 173: 545-560.
Steeg PS, Camphausen KA and Smith QR: Brain metastases as preventive and therapeutic targets. Nat Rev Cancer (2011) 11: 352-363.
Jones TR, Ruoslahti E, Schold SC and Bigner DD: Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. Cancer Res (1982) 42: 168-177.
Bellon G, Caulet T, Cam Y, Pluot M, Poulin G, Pytlinska M and Bernard MH: Immunohistochemical localisation of macromolecules of the basement membrane and extracellular matrix of human gliomas and meningiomas. Acta Neuropathol (1985) 66: 245-252.
Gladson CL: The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol (1999) 58: 1029-1040.
Winkler F, Kienast Y, Fuhrmann M, Von Baumgarten L, Burgold S, Mitteregger G, Kretzschmar H and Herms J: Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis. Glia (2009) 57: 1306-1315.
Watkins S, Robel S, Kimbrough IF, Robert SM, Ellis-Davies G and Sontheimer H: Disruption of astrocyte-vascular coupling and the bloodbrain barrier by invading glioma cells. Nat Commun (2014) 5: 4196.
Montana V and Sontheimer H: Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci (2011) 31: 4858-4867.
Inoue S, Ichikawa T, Kurozumi K, Maruo T, Onishi M, Yoshida K, Fujii K, Kambara H, Chiocca EA and Date I: Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg (2012) 78: 670-682.
Maruo T, Ichikawa T, Kanzaki H, Inoue S, Kurozumi K, Onishi M, Yoshida K, Kambara H, Ouchida M, Shimizu K, Tamaru S, Chiocca EA and Date I: Proteomics-based analysis of invasion-related proteins in malignant gliomas. Neuropathology (2013) 33: 264-275.
Onishi M, Ichikawa T, Kurozumi K, Inoue S, Maruo T, Otani Y, Fujii K, Ishida J, Shimazu Y, Yoshida K, Michiue H, Antonio Chiocca E and Date I: Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma. Brain Tumor Pathol (2015) 32: 184-194.
Hajjar KA, Guevara CA, Lev E, Dowling K and Chacko J: Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface. Essential role of endonexin repeat 2. J Biol Chem (1996) 271: 21652-21659.
Gerke V and Moss SE: Annexins: from structure to function. Physiol Rev (2002) 82: 331-371.
Rescher U, Ruhe D, Ludwig C, Zobiack N and Gerke V: Annexin 2 is a phosphatidylinositol (4, 5)-bisphosphate binding protein recruited to actin assembly sites at cellular membranes. J Cell Sci (2004) 117: 3473-3480.
Courtneidge S, Ralston R, Alitalo K and Bishop JM: Subcellular location of an abundant substrate (p36) for tyrosine-specific protein kinases. Mol Cell Biol (1983) 3: 340-350.
Eberhard DA, Karns LR, VandenBerg SR and Creutz CE: Control of the nuclear-cytoplasmic partitioning of annexin II by a nuclear export signal and by p11 binding. J Cell Sci (2001) 114: 3155-3166.
Jost M, Thiel C, Weber K and Gerke V: Mapping of three unique Ca(2+)-binding sites in human annexin II. Eur J Biochem (1992) 207: 923-930.
Jost M, Weber K and Gerke V: Annexin II contains two types of Ca(2+)-binding sites. Biochem J (1994) 298 Pt 3: 553-559.
Filipenko NR, Kang HM and Waisman DM: Characterization of the Ca2+-binding sites of annexin II tetramer. J Biol Chem (2000) 275: 38877-38884.
Filipenko NR and Waisman DM: The C terminus of annexin II mediates binding to F-actin. J Biol Chem (2001) 276: 5310-5315.
Hayes MJ, Shao D, Bailly M and Moss SE: Regulation of actin dynamics by annexin 2. Embo j (2006) 25: 1816-1826.
Jacovina AT, Deora AB, Ling Q, Broekman MJ, Almeida D, Greenberg CB, Marcus AJ, Smith JD and Hajjar KA: Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis. J Clin Invest (2009) 119: 3384-3394.
Mai J, Waisman DM and Sloane BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta (2000) 1477: 215-230.
Sharma M, Ownbey RT and Sharma MC: Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol (2010) 88: 278-286.
Valapala M, Thamake SI and Vishwanatha JK: A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. J Cell Sci (2011) 124: 1453-1464.
Yamada A, Irie K, Hirota T, Ooshio T, Fukuhara A and Takai Y: Involvement of the annexin II-S100A10 complex in the formation of E-cadherin-based adherens junctions in Madin-Darby canine kidney cells. J Biol Chem (2005) 280: 6016-6027.
Gould KL, Woodgett JR, Isacke CM and Hunter T: The protein-tyrosine kinase substrate p36 is also a substrate for protein kinase C in vitro and in vivo. Mol Cell Biol (1986) 6: 2738-2744.
Jost M and Gerke V: Mapping of a regulatory important site for protein kinase C phosphorylation in the N-terminal domain of annexin II. Biochim Biophys Acta (1996) 1313: 283-289.
Liu J and Vishwanatha JK: Regulation of nucleo-cytoplasmic shuttling of human annexin A2: a proposed mechanism. Mol Cell Biochem (2007) 303: 211-220.
Hirata E, Yukinaga H, Kamioka Y, Arakawa Y, Miyamoto S, Okada T, Sahai E and Matsuda M: In vivo fluorescence resonance energy transfer imaging reveals differential activation of Rho-family GTPases in glioblastoma cell invasion. J Cell Sci (2012) 125: 858-868.
Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, Um JY, Kim WK, Lee JK, Park J, Kim EH, Lee JH, Lee JH, Chung WS, Ju YS, Park SH, Chang JH, Kang SG and Lee JH: Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature (2018) 560: 243-247.
Quinones-Hinojosa A, Sanai N, Soriano-Navarro M, Gonzalez-Perez O, Mirzadeh Z, Gil-Perotin S, Romero-Rodriguez R, Berger MS, Garcia- Verdugo JM and Alvarez-Buylla A: Cellular composition and cytoarchitecture of the adult human subventricular zone: a niche of neural stem cells. J Comp Neurol (2006) 494: 415-434.
Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, Lawton MT, McDermott MW, Parsa AT, Manuel-Garcia Verdugo J, Berger MS and Alvarez-Buylla A: Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature (2004) 427: 740-744.
Sanai N, Nguyen T, Ihrie RA, Mirzadeh Z, Tsai HH, Wong M, Gupta N, Berger MS, Huang E, Garcia-Verdugo JM, Rowitch DH and Alvarez- Buylla A: Corridors of migrating neurons in the human brain and their decline during infancy. Nature (2011) 478: 382-386.
Marin O and Rubenstein JL: Cell migration in the forebrain. Annu Rev Neurosci (2003) 26: 441-483.
Breuss MW, Leca I, Gstrein T, Hansen AH and Keays DA: Tubulins and brain development - The origins of functional specification. Mol Cell Neurosci (2017) 84: 58-67.
Kaneko N, Sawada M and Sawamoto K: Mechanisms of neuronal migration in the adult brain. J Neurochem (2017) 141: 835-847.
Yamashita T, Ninomiya M, Hernandez Acosta P, Garcia-Verdugo JM, Sunabori T, Sakaguchi M, Adachi K, Kojima T, Hirota Y, Kawase T, Araki N, Abe K, Okano H and Sawamoto K: Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the poststroke adult striatum. J Neurosci (2006) 26: 6627-6636.
Schaar BT and McConnell SK: Cytoskeletal coordination during neuronal migration. Proc Natl Acad Sci U S A (2005) 102: 13652-13657.
Kengaku M: Cytoskeletal control of nuclear migration in neurons and non-neuronal cells. Proc Jpn Acad Ser B Phys Biol Sci (2018) 94: 337-349.
Monzo P, Chong YK, Guetta-Terrier C, Krishnasamy A, Sathe SR, Yim EK, Ng WH, Ang BT, Tang C, Ladoux B, Gauthier NC and Sheetz MP: Mechanical confinement triggers glioma linear migration dependent on formin FHOD3. Mol Biol Cell (2016) 27: 1246-1261.
Panopoulos A, Howell M, Fotedar R and Margolis RL: Glioblastoma motility occurs in the absence of actin polymer. Mol Biol Cell (2011) 22: 2212-2220.
Lehtimaki J, Hakala M and Lappalainen P: Actin Filament Structures in Migrating Cells. Handb Exp Pharmacol (2017) 235: 123-152.
Nobes CD and Hall A: Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell (1995) 81: 53-62.
Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, Nakada M, Cunliffe HE, Hostetter G, Hoelzinger DB, Rennert JL, Michaelson JS, Burkly LC, Lipinski CA, Loftus JC, Mariani L and Berens ME: Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res (2006) 66: 9535-9542.
Salhia B, Tran NL, Chan A, Wolf A, Nakada M, Rutka F, Ennis M, McDonough WS, Berens ME, Symons M and Rutka JT: The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol (2008) 173: 1828-1838.
Fortin Ensign SP, Mathews IT, Symons MH, Berens ME and Tran NL: Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression. Front Oncol (2013) 3: 241.
Chan AY, Coniglio SJ, Chuang Y-y, Michaelson D, Knaus UG, Philips MR and Symons M: Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene (2005) 24: 7821.
Pollard TD, Blanchoin L and Mullins RD: Molecular mechanisms controlling actin filament dynamics in nonmuscle cells. Annu Rev Biophys Biomol Struct (2000) 29: 545-576.
Takenawa T and Suetsugu S: The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol (2007) 8: 37-48.
Raftopoulou M and Hall A: Cell migration: Rho GTPases lead the way. Dev Biol (2004) 265: 23-32.
Akhshi TK, Wernike D and Piekny A: Microtubules and actin crosstalk in cell migration and division. Cytoskeleton (Hoboken) (2014) 71: 1-23.
Fife CM, McCarroll JA and Kavallaris M: Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol (2014) 171: 5507-5523.
Leduc C and Etienne-Manneville S: Intermediate filaments in cell migrationand invasion: the unusual suspects. Curr Opin Cell Biol (2015) 32: 102-112.
Rogel MR, Soni PN, Troken JR, Sitikov A, Trejo HE and Ridge KM: Vimentin is sufficient and required for wound repair and remodeling in alveolar epithelial cells. Faseb j (2011) 25: 3873-3883.
Lendahl U, Zimmerman LB and McKay RD: CNS stem cells express a new class of intermediate filament protein. Cell (1990) 60: 585-595.
Zhao J, Zhang L, Dong X, Liu L, Huo L and Chen H: High Expression of Vimentin is Associated With Progression and a Poor Outcome in Glioblastoma. Appl Immunohistochem Mol Morphol (2018) 26: 337-344.
Kitai R, Horita R, Sato K, Yoshida K, Arishima H, Higashino Y, Hashimoto N, Takeuchi H, Kubota T and Kikuta K: Nestin expression in astrocytic tumors delineates tumor infiltration. Brain Tumor Pathol (2010) 27: 17-21.
Ishiwata T, Teduka K, Yamamoto T, Kawahara K, Matsuda Y and Naito Z: Neuroepithelial stem cell marker nestin regulates the migration, invasion and growth of human gliomas. Oncol Rep (2011) 26: 91-99.
Luduena RF: A hypothesis on the origin and evolution of tubulin. Int Rev Cell Mol Biol (2013) 302: 41-185.
Akhmanova A and Steinmetz MO: Microtubule +TIPs at a glance. J Cell Sci (2010) 123: 3415-3419.
Boyne LJ, Martin K, Hockfield S and Fischer I: Expression and distribution of phosphorylated MAP1B in growing axons of cultured hippocampal neurons. J Neurosci Res (1995) 40: 439-450.
Mohan R and John A: Microtubule-associated proteins as direct crosslinkers of actin filaments and microtubules. IUBMB Life (2015) 67: 395-403.
Tlhyama T, Lee VM and Trojanowski JQ: Co-expression of low molecular weight neurofilament protein and glial fibrillary acidic protein in established human glioma cell lines. Am J Pathol (1993) 142: 883-892.
Zhou Y, Wu S, Liang C, Lin Y, Zou Y, Li K, Lu B, Shu M, Huang Y, Zhu W, Kang Z, Xu D, Hu J and Yan G: Transcriptional upregulation of microtubule-associated protein 2 is involved in the protein kinase A-induced decrease in the invasiveness of glioma cells. Neuro Oncol (2015) 17: 1578-1588.
Moores CA, Perderiset M, Francis F, Chelly J, Houdusse A and Milligan RA: Mechanism of microtubule stabilization by doublecortin. Mol Cell (2004) 14: 833-839.
Francis F, Koulakoff A, Boucher D, Chafey P, Schaar B, Vinet MC, Friocourt G, McDonnell N, Reiner O, Kahn A, McConnell SK, Berwald- Netter Y, Denoulet P and Chelly J: Doublecortin is a developmentally regulated, microtubule-associated protein expressed in migrating and differentiating neurons. Neuron (1999) 23: 247-256.
Gleeson JG, Lin PT, Flanagan LA and Walsh CA: Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons. Neuron (1999) 23: 257-271.
Wang C, Liu F, Liu YY, Zhao CH, You Y, Wang L, Zhang J, Wei B, Ma T, Zhang Q, Zhang Y, Chen R, Song H and Yang Z: Identification and characterization of neuroblasts in the subventricular zone and rostral migratory stream of the adult human brain. Cell Res (2011) 21: 1534-1550.
Gleeson JG, Allen KM, Fox JW, Lamperti ED, Berkovic S, Scheffer I, Cooper EC, Dobyns WB, Minnerath SR, Ross ME and Walsh CA: Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein. Cell (1998) 92: 63-72.
Daou MC, Smith TW, Litofsky NS, Hsieh CC and Ross AH: Doublecortin is preferentially expressed in invasive human brain tumors. Acta Neuropathol (2005) 110: 472-480.
Ortensi B, Osti D, Pellegatta S, Pisati F, Brescia P, Fornasari L, Levi D, Gaetani P, Colombo P, Ferri A, Nicolis S, Finocchiaro G and Pelicci G: Rai is a new regulator of neural progenitor migration and glioblastoma invasion. Stem Cells (2012) 30: 817-832.
Ohshima T, Ogawa M, Veeranna, Hirasawa M, Longenecker G, Ishiguro K, Pant HC, Brady RO, Kulkarni AB and Mikoshiba K: Synergistic contributions of cyclin-dependant kinase 5/p35 and Reelin/Dab1 to the positioning of cortical neurons in the developing mouse brain. Proc Natl Acad Sci U S A (2001) 98: 2764-2769.
Tanaka T, Serneo FF, Tseng HC, Kulkarni AB, Tsai LH and Gleeson JG: Cdk5 phosphorylation of doublecortin ser297 regulates its effect on neuronal migration. Neuron (2004) 41: 215-227.
Liu R, Tian B, Gearing M, Hunter S, Ye K and Mao Z: Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc Natl Acad Sci U S A (2008) 105: 7570-7575.
Ren Y, Zhou X, Yang JJ, Liu X, Zhao XH, Wang QX, Han L, Song X, Zhu ZY, Tian WP, Zhang L, Mei M and Kang CS: AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis. Cancer Lett (2015) 362: 174-182.
Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee WK and Cheng SY: EGFRvIII stimulates glioma growth and invasion through PKAdependent serine phosphorylation of Dock180. Oncogene (2014) 33: 2504-2512.
Knobbe CB, Merlo A and Reifenberger G: Pten signaling in gliomas. Neuro Oncol (2002) 4: 196-211.
Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ and Muir WJ: Schizophrenia and affective disorders--cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet (2001) 69: 428-433.
Morris JA, Kandpal G, Ma L and Austin CP: DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum Mol Genet (2003) 12: 1591-1608.
Gao X, Mi Y, Guo N, Hu Z, Hu F, Liu D, Gao L, Gou X and Jin W: Disrupted in schizophrenia 1 (DISC1) inhibits glioblastoma development by regulating mitochondria dynamics. Oncotarget (2016) 7: 85963-85974.
Sobel A, Boutterin MC, Beretta L, Chneiweiss H, Doye V and Peyro-Saint-Paul H: Intracellular substrates for extracellular signaling. Characterization of a ubiquitous, neuron-enriched phosphoprotein (stathmin). J Biol Chem (1989) 264: 3765-3772.
Niethammer P, Bastiaens P and Karsenti E: Stathmin-tubulin interaction gradients in motile and mitotic cells. Science (2004) 303: 1862-1866.
Wittmann T, Bokoch GM and Waterman-Storer CM: Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem (2004) 279: 6196-6203.
Rana S, Maples PB, Senzer N and Nemunaitis J: Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther (2008) 8: 1461-1470.
Song Y, Mu L, Han X, Liu X and Fu S: siRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cell lines. Acta Biochim Biophys Sin (Shanghai) (2014) 46: 1034-1040.
Liu P, Yu J, Tian X, Chang J, Zhang Y, Zhang R, Zhang N, Huang R, Li L, Qiao X and Guo H: The effect of downregulation of Stathmin gene on biological behaviors of U373 and U87-MG glioblastoma cells. Biol Res (2018) 51: 16.
Salinas S, Carazo-Salas RE, Proukakis C, Schiavo G and Warner TT: Spastin and microtubules: Functions in health and disease. J Neurosci Res (2007) 85: 2778-2782.
Draberova E, Vinopal S, Morfini G, Liu PS, Sladkova V, Sulimenko T, Burns MR, Solowska J, Kulandaivel K, de Chadarevian JP, Legido A, Mork SJ, Janacek J, Baas PW, Draber P and Katsetos CD: Microtubulesevering ATPase spastin in glioblastoma: increased expression in human glioblastoma cell lines and inverse roles in cell motility and proliferation. J Neuropathol Exp Neurol (2011) 70: 811-826.
Wu QF, Yang L, Li S, Wang Q, Yuan XB, Gao X, Bao L and Zhang X: Fibroblast growth factor 13 is a microtubule-stabilizing protein regulating neuronal polarization and migration. Cell (2012) 149: 1549-1564.
Smallwood PM, Munoz-Sanjuan I, Tong P, Macke JP, Hendry SH, Gilbert DJ, Copeland NG, Jenkins NA and Nathans J: Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc Natl Acad Sci U S A (1996) 93: 9850-9857.
Nishimoto S and Nishida E: Fibroblast growth factor 13 is essential for neural differentiation in Xenopus early embryonic development. J Biol Chem (2007) 282: 24255-24261.
Fang X, Yoon JG, Li L, Yu W, Shao J, Hua D, Zheng S, Hood L, Goodlett DR, Foltz G and Lin B: The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics (2011) 12: 11.
Berezovsky AD, Poisson LM, Cherba D, Webb CP, Transou AD, Lemke NW, Hong X, Hasselbach LA, Irtenkauf SM, Mikkelsen T and deCarvalho AC: Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. Neoplasia (2014) 16: 193-206, 206. e119-125.
Wang J, Xu SL, Duan JJ, Yi L, Guo YF, Shi Y, Li L, Yang ZY, Liao XM, Cai J, Zhang YQ, Xiao HL, Yin L, Wu H, Zhang JN, Lv SQ, Yang QK, Yang XJ, Jiang T, Zhang X, Bian XW and Yu SC: Invasion of white matter tracts by glioma stem cells is regulated by a NOTCH1-SOX2 positive- feedback loop. Nat Neurosci (2019) 22: 91-105.
Mimori-Kiyosue Y, Shiina N and Tsukita S: The dynamic behavior of the APC-binding protein EB1 on the distal ends of microtubules. Curr Biol (2000) 10: 865-868.
Perez F, Diamantopoulos GS, Stalder R and Kreis TE: CLIP-170 highlights growing microtubule ends in vivo. Cell (1999) 96: 517-527.
Berges R, Baeza-Kallee N, Tabouret E, Chinot O, Petit M, Kruczynski A, Figarella-Branger D, Honore S and Braguer D: End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo. Oncotarget (2014) 5: 12769-12787.
Dong X, Liu F, Sun L, Liu M, Li D, Su D, Zhu Z, Dong JT, Fu L and Zhou J: Oncogenic function of microtubule end-binding protein 1 in breast cancer. J Pathol (2010) 220: 361-369.
Wang Y, Zhou X, Zhu H, Liu S, Zhou C, Zhang G, Xue L, Lu N, Quan L, Bai J, Zhan Q and Xu N: Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway. Oncogene (2005) 24: 6637-6645.
Nishigaki R, Osaki M, Hiratsuka M, Toda T, Murakami K, Jeang KT, Ito H, Inoue T and Oshimura M: Proteomic identification of differentiallyexpressed genes in human gastric carcinomas. Proteomics (2005) 5: 3205-3213.
Fujii K, Kondo T, Yokoo H, Yamada T, Iwatsuki K and Hirohashi S: Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics (2005) 5: 1411-1422.
Li L and Yang XJ: Tubulin acetylation: responsible enzymes, biological functions and human diseases. Cell Mol Life Sci (2015) 72: 4237-4255.
Magiera MM, Singh P, Gadadhar S and Janke C: Tubulin Posttranslational Modifications and Emerging Links to Human Disease. Cell (2018) 173: 1323-1327.
Westermann S and Weber K: Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol (2003) 4: 938-947.
Janke C and Bulinski JC: Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat Rev Mol Cell Biol (2011) 12: 773-786.
Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP: HDAC6 is a microtubule-associated deacetylase. Nature (2002) 417: 455-458.
Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB and Martin SS: alpha-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res (2015) 75: 203-215.
Wu Y, Song SW, Sun J, Bruner JM, Fuller GN and Zhang W: IIp45 inhibits cell migration through inhibition of HDAC6. J Biol Chem (2010) 285: 3554-3560.
Balabanian L, Berger CL and Hendricks AG: Acetylated Microtubules Are Preferentially Bundled Leading to Enhanced Kinesin-1 Motility. Biophys J (2017) 113: 1551-1560.
Yokota T, Kouno J, Adachi K, Takahashi H, Teramoto A, Matsumoto K, Sugisaki Y, Onda M and Tsunoda T: Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin. Acta Neuropathol (2006) 111: 29-38.
Wang H, Feng W, Lu Y, Li H, Xiang W, Chen Z, He M, Zhao L, Sun X, Lei B, Qi S and Liu Y: Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide. Sci Rep (2016) 6: 28948.
Neubauer HA, Tea MN, Zebol JR, Gliddon BL, Stefanidis C, Moretti PAB, Pitman MR, Costabile M, Kular J, Stringer BW, Day BW, Samuel MS, Bonder CS, Powell JA and Pitson SM: Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma. Oncogene (2018) 38: 1151-1165.
Brehar FM, Gafencu AV, Trusca VG, Fuior EV, Arsene D, Amaireh M, Giovani A and Gorgan MR: Preferential Association of Lissencephaly-1 Gene Expression with CD133+ Glioblastoma Cells. J Cancer (2017) 8: 1284-1291.
Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q, Sims PA, Canoll P, Summers MK, Rosenfeld SS and Rich JN: The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med (2015) 7: 304ra143.
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC and Elmquist WF: Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol (2018) 20: 184-191.
Canta A, Chiorazzi A and Cavaletti G: Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem (2009) 16: 1315-1324.
Oehler C, Frei K, Rushing EJ, McSheehy PM, Weber D, Allegrini PR, Weniger D, Lutolf UM, Knuth A, Yonekawa Y, Barath K, Broggini- Tenzer A, Pruschy M and Hofer S: Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology (2012) 83: 1-9.
Pagano A, Honore S, Mohan R, Berges R, Akhmanova A and Braguer D: Epothilone B inhibits migration of glioblastoma cells by inducing microtubule catastrophes and affecting EB1 accumulation at microtubule plus ends. Biochem Pharmacol (2012) 84: 432-443.
Berges R, Balzeau J, Peterson AC and Eyer J: A tubulin binding peptide targets glioma cells disrupting their microtubules, blocking migration, and inducing apoptosis. Mol Ther (2012) 20: 1367-1377.
Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp ES, HerndonJE, 2nd, McSherry F, Desjardins A, Randazzo D, Friedman HS and Peters KB: Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. Oncologist (2018) 23: 157-e121.
Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD and Wen PY: Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res (2012) 18: 6032-6039.
Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF, Jr., Zwiebel J and Buckner JC: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 27: 2052-2058.
Zhang I, Beus M, Stochaj U, Le PU, Zorc B, Rajic Z, Petrecca K and Maysinger D: Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule. Cell Death Discov (2018) 4: 41.
Wang Z, Hu P, Tang F, Lian H, Chen X, Zhang Y, He X, Liu W and Xie C: HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma. Cancer Lett (2016) 379: 134-142.
Yang W, Liu Y, Gao R, Yu H and Sun T: HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway. Cancer Lett (2018) 415: 164-176
Nakashima H, Kaufmann JK, Wang PY, Nguyen T, Speranza MC,Kasai K, Okemoto K, Otsuki A, Nakano I, Fernandez S, Goins WF, Grandi P, Glorioso JC, Lawler S, Cripe TP and Chiocca EA: Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J Clin Invest (2015) 125: 4269-4280.
Kim EH, Song HS, Yoo SH and Yoon M: Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. Oncotarget (2016) 7: 65125-65136.